Results: Fourteen patients received abiraterone or enzalutamide prior to docetaxel and sixteen patients received placebo followed by docetaxel (control group). We are currently undertaking analysis of response rates, progression free survival and overall survival following docetaxel and statistical comparisons between the groups. This analysis will be available for a poster presentation. Comparison will also be made with historical data of docetaxel activity in CRPC.

Conclusions: Our analysis is the first to investigate the efficacy of docetaxel chemotherapy in men with CRPC who have previously received treatment with enzalutamide or abiraterone. The possibility of cross resistance between these agents requires careful investigation to determine optimal sequencing and potential combinations.

Reference
1. van Soest R.J., van Royen M.E., de Morree E.S. et al. Cross-Resistance with enzalutamide or abiraterone. The possibility of cross resistance between docetaxel activity in CRPC.